In the context of Investigational Medicinal Products, which aspect should be well characterized in formulations used in clinical trials?

• A. Bioavailability information wherever feasible
• B. Manufacturing facility location and batch size
• C. Toxicology data from animal studies
• D. Marketing strategy and pricing

Answer: (A)

Understanding how the formulation behaves in the body, i.e., its bioavailability, is essential for Investigational Medicinal Products. When the formulation’s absorption and systemic exposure are well characterized, dose selection and interpretation of safety and efficacy data become reliable. This information helps ensure that participants receive consistent exposure across different batches and study sites, and it supports meaningful PK analyses within the trial.

Other aspects like where a manufacturing facility is located or batch size fall under quality systems and manufacturing controls, not the in vivo behavior of the formulation. Toxicology data from animal studies informs safety assessment, not how the formulation is absorbed in humans. Marketing strategy and pricing have no bearing on the formulation’s bioavailability or trial interpretation.